Cyclic peptidomimetic for the treatment of neurological disorders
AssigneeBrown University
InventorJohn Marshall
Life of this patent
Estimating the term…
Abstract
The present invention provides to compositions and methods useful in the treatment of neurological disorders including, but not limited to, Angelman syndrome, depression, traumatic brain injury, stroke, and Alzheimer's disease. CN2097, a rationally designed cyclic peptidomimetic drug that has been demonstrated to have effectiveness in preclinical models for the treatment of neurological disorders, is rapidly cleared and has a short half-life. The present invention provides a stable analog of CN2097.
Claims6
A composition comprising a therapeutically effective amount of dR7-2097 or a pharmaceutically acceptable salt thereof, wherein the dR7-2097 comprises RRRRRRRC (SEQ ID NO:
- 2 or PolyArg) in the following dR7-2097 structure:
- wherein the PolyArg consists of all the R enantiomer, (R)-Arg or (“R”)-arginine, and all the S enantiomer, (“S”)-cysteine amino acids in the RRRRRRRC (SEQ ID NO:
- 2);
- and
- wherein in the dR7-2097 there is a disulfide linkage from the(S)-Cys or (“S”)-cysteine to one (R)-Cys or (“R”)-cysteine.
Dependencies are inferred from the claim text.